Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Brendan M. O’malley Purchases 7,500 Shares

Abeona Therapeutics Inc (NASDAQ:ABEOGet Rating) SVP Brendan M. O’malley purchased 7,500 shares of the firm’s stock in a transaction dated Friday, November 18th. The shares were bought at an average cost of $3.99 per share, for a total transaction of $29,925.00. Following the completion of the purchase, the senior vice president now directly owns 87,961 shares of the company’s stock, valued at $350,964.39. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Abeona Therapeutics Stock Up 2.0 %

Shares of NASDAQ ABEO opened at $4.12 on Tuesday. The company’s fifty day moving average is $3.95 and its 200-day moving average is $4.13. The stock has a market cap of $24.51 million, a price-to-earnings ratio of -0.23 and a beta of 1.27. Abeona Therapeutics Inc has a twelve month low of $2.70 and a twelve month high of $20.74.

Analysts Set New Price Targets

Several analysts have recently commented on ABEO shares. Alliance Global Partners began coverage on shares of Abeona Therapeutics in a research note on Thursday, September 15th. They set a “buy” rating on the stock. Cantor Fitzgerald raised their price objective on shares of Abeona Therapeutics from $22.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, November 8th. Finally, StockNews.com raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 16th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $55.00.

Hedge Funds Weigh In On Abeona Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Citigroup Inc. bought a new position in shares of Abeona Therapeutics during the first quarter worth $27,000. State Street Corp boosted its position in shares of Abeona Therapeutics by 24.6% during the second quarter. State Street Corp now owns 377,402 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 74,600 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Abeona Therapeutics during the third quarter worth $103,000. Worth Venture Partners LLC boosted its position in shares of Abeona Therapeutics by 9.5% during the first quarter. Worth Venture Partners LLC now owns 1,244,774 shares of the biopharmaceutical company’s stock worth $392,000 after purchasing an additional 107,500 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Abeona Therapeutics by 3.1% during the second quarter. Renaissance Technologies LLC now owns 2,398,166 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 72,350 shares in the last quarter.

About Abeona Therapeutics

(Get Rating)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Featured Stories

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.